Skip to main content

April 2013 Vol 6 No 3 Payers’ Guide to New FDA Approvals

Payers' Guide, FDA Approvals

Tudorza Pressair: A Novel Oral Inhalation Therapy for the Maintenance Treatment of Chronic Obstructive Pulmonary Disease–Associated Bronchospasm

Payers' Guide, FDA Approvals

Vascepa: First EPA-Only Omega-3 Therapy Approved by the FDA for Severe Hypertriglyceridemia

Payers' Guide, FDA Approvals

Eliquis Approved by the FDA to Reduce the Risks of Stroke and Systemic Embolism in Patients with Atrial Fibrillation

Payers' Guide, FDA Approvals

The Health Burden of Multiple Myeloma: Subcutaneous Velcade a New, Convenient Route of Administration Option

Rhonda Williams, Medical Writer

Payers' Guide, FDA Approvals

Kyprolis: A New Treatment Option for Patients with Relapsed/Refractory Multiple Myeloma Previously Treated with Bortezomib and an Immunomodulatory Agent

Lynne Lederman, PhD, Medical Writer

Payers' Guide, FDA Approvals

Jentadueto: A New Oral Antihyperglycemic Combination Therapy for Patients with Type 2 Diabetes

Wayne Kuznar, Medical Writer

Payers' Guide, FDA Approvals

Abraxane Receives New Indication for Locally Advanced or Metastatic Non–Small-Cell Lung Cancer When Curative Surgery or Radiation Therapy Is Not an Option

Lynne Lederman, PhD

FDA Approvals, Payers' Guide

FDA Approvals of Brand-Name Prescription Drugs in 2012

FDA Approvals, Payers' Guide

Foreword: The Fourth Annual Payers’ Guide to New FDA Approvals

FDA Approvals, Payers' Guide

Introduction: New FDA Drug Approvals in 2012: A 15-Year High

Gary M. Owens, MD

Page 2 of 2
Results 11 - 20 of 20